Genomadix

Genomadix is a biotechnology startup based in Ottawa, Canada that is revolutionizing diagnostics with its flagship product, the Genomadix Cube. This real-time qPCR point-of-need technology allows for fast, portable, and accurate DNA results, bringing lab-quality results without the need for a traditional laboratory. The company is dedicated to maintaining the highest level of customer satisfaction, quality, and support, and holds ISO 13485 medical device development and manufacturing standards certification. The Genomadix Cube is a real-time polymerase chain reaction (PCR) molecular diagnostic instrument that can perform tests for precision medicine genotyping and environmental targets on a sample-to-result platform. Its portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform offers tests for Rapid CYP2C19 Genotyping (FDA 510(k)-Cleared and CE Marked), Environmental water testing for Legionella pneumophila, and Apolipoprotein E (ApoE) RUO genotyping. Additionally, it is available as an open platform called CubeX, allowing users to run any qPCR tests for research use only. Notably, Genomadix's technology for the cube includes over 3 million hours of research and development, 11 patents, and 30 peer-reviewed scientific publications. Founded in 2021, the company recently secured a Corporate Round investment on 29 August 2022 from the renowned Mayo Clinic, signifying a strong validation of their innovative approach to diagnostics.